Key features and details
- Expression system: Escherichia coli
- Purity: > 95% SDS-PAGE
- Suitable for: SDS-PAGE, ELISA, WB
Product nameRecombinant Hepatitis B Virus Core Antigen protein
See all Hepatitis B Virus Core Antigen proteins and peptides
Biological activityReacts strongly with human HBV positive serum.
Purity> 95 % SDS-PAGE.
Purification method is proprietary.
Expression systemEscherichia coli
Protein lengthFull length protein
SequenceMDIDPYKEFG ATVELLSFLP SDFFPSVRDL LDNASALYRE ALESPEHCSP HHTALRQAIL CWGELMTLAT WVGGNLEDPI SRDLVVSYVN TNMGLKFRQL LWFHISCLTF GRETVIEYLV SFGVWIRTPP AYRPPNAPIL STLPETTVVR RRGRSPRRRT PSPRRRRSQS PRRRRSQSRE SQC
Predicted molecular weight18 kDa
Amino acids1 to 183
Our Abpromise guarantee covers the use of ab49013 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Additional notesReacts strongly with human HBV positive serum.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Constituents: 0.02% PBS, 50% Glycerol (glycerin, glycerine), 0.435% Sodium chloride
- Capsid protein
RelevanceHepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection. The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection.
Cellular localizationCapsid protein: Virion. Host cytoplasm, hepatocyte nucleus.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab49013 has been referenced in 1 publication.
- Toyama M et al. Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. Virus Res 271:197677 (2019). PubMed: 31376401